Longacre Square Partners guided Mind Medicine as the psychedelic drug company declared victory in the proxy contest against FCM MM Holdings, a group that included its co-founder and former chairman Scott Freeman.

MindMed announced June 21 that all six of its nominees were elected to the board, according to a preliminary vote count.

CEO Robert Barrow thanked shareholders for their support and independent proxy advisors Institutional Shareholder Services and Glass Lewis & Co. for their recommendations.

He’s glad to ”put the proxy contest behind us and fully focus on bringing our transformative therapies to market in order to help patients in need and deliver value for all shareholders.”

Longacre Square’s Dan Zacchei, Joe Germani, Miller Winston and Olivia McCann represented MindMed.

Gagnier Communications’ Dan Gagnier and Riyaz Lalani handled FCM.